• 1
    Urakami K, Adachi Y, Wakutani Y et al. Epidemiologic and genetic studies of dementia of the Alzheimer type in Japan. Dement Geriatr Cogn Disord 1998; 9: 294298.
  • 2
    Yamada T, Hattori H, Miura A, Tanabe M, Yamori Y. Prevalence of Alzheimer's disease, vascular dementia and dementia with Lewy bodies in a Japanese population. Psychiatry Clin Neurosci 2001; 55: 2125.
  • 3
    Motter R, Vigo-Pelfrey C, Kholodenko D et al. Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol 1995; 38: 643648.
  • 4
    Kanai M, Matsubara E, Isoe K et al. Longitudinal study of cerebrospinal fluid levels of tau, A beta1–40, and A beta1–42(43) in Alzheimer's disease: a study in Japan. Ann Neurol 1998; 44: 1726.
  • 5
    Ishiguro K, Ohno H, Arai H et al. Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer's disease. Neurosci Lett 1999; 270: 9194.
  • 6
    Schonknecht P, Pantela J, Hunta A et al. Levels of total tau and tau protein phosphorylated at threonine 181 in patients with incipient and manifest Alzheimer's disease. Neurosci Lett 2003; 339: 172174.
  • 7
    Blennow K, Vanmechelen E, Hampel H. CSF total tau, Abeta42 and phosphorylated tau protein as biomarkers for Alzheimer's disease. Mol Neurobiol 2001; 24: 8797.
  • 8
    Maddalena A, Papassotiropoulos A, Müller-Tillmanns B et al. Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to beta-amyloid peptide42. Arch Neurol 2003; 60: 12021206.
  • 9
    Imabayashi E, Matsuda H, Asada T et al. Superiority of three-dimensional stereotactic surface projection analysis over visual inspection in discrimination of very early Alzheimer's disease from controls using brain perfusion SPECT. J Nucl Med 2004; 45: 14501457.
  • 10
    Drzezga A, Lautenschlager N, Siebner H et al. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study. Eur J Nucl Med Mol Imaging 2003; 30: 11041113.
  • 11
    Johnson KA, Jones BL, Holman JA et al. Preclinical prediction of Alzheimer's disease using SPECT. Neurology 1998; 50: 15631571.
  • 12
    Kogure D, Matsuda H, Ohnishi T et al. Longitudinal evaluation of early Alzheimer's disease using brain perfusion SPECT. J Nucl Med 2000; 41: 11551162.
  • 13
    Matsuda H. Cerebral blood flow and metabolic abnormalities in Alzheimer's disease. Ann Nucl Med 2001; 15: 8592.
  • 14
    Babiloni C, Binetti G, Cassetta E et al. Mapping distributed sources of cortical rhythms in mild Alzheimer's disease. A multi-centric EEG study. Neuroimage 2004; 22: 5767.
  • 15
    Dierks T, Ihl R, Frolich L, Maurer K. Dementia of the Alzheimer type: effects on the spontaneous EEG described by dipole sources. Psychiatry Res 1993; 50: 151162.
  • 16
    Huang C, Wahlund L, Dierks T, Julin P, Winblad B, Jelic V. Discrimination of Alzheimer's disease and mild cognitive impairment by equivalent EEG sources: a cross-sectional and longitudinal study. Clin Neurophysiol 2000; 111: 19611967.
  • 17
    Babiloni C, Ferri R, Binetti G et al. Fronto-parietal coupling of brain rhythms in mild cognitive impairment: a multicentric EEG study. Brain Res Bull 2006; 69: 6373.
  • 18
    Jeong J, Gore JC, Peterson BS. Mutual information analysis of the EEG in patients with Alzheimer's disease. Clin Neurophysiol 2001; 112: 827835.
  • 19
    Babiloni C, Frisoni GB, Pievani M et al. Hippocampal volume and cortical sources of EEG alpha rhythms in mild cognitive impairment and Alzheimer disease. Neuroimage 2009; 44: 123135.
  • 20
    Musha T, Asada T, Yamashita F et al. A new EEG method for estimating cortical neuronal impairment that is sensitive to early stage Alzheimer's disease. Clin Neurophysiol 2002; 113: 10521058.
  • 21
    Adler G, Brassen S, Jajcevic A. EEG coherence in Alzheimer's dementia. J Neural Transm 2003; 110: 10511058.
  • 22
    Fonseca LC, Tedrus GM, Prandi LR, Andrade AC. Quantitative electroencephalography power and coherence measurements in the diagnosis of mild and moderate Alzheimer's disease. Arq Neuropsiquiatr 2011; 69: 297303.
  • 23
    Folstein MF, Folstein SE, McHuge PR. ‘Mini-mental State’ a practical method for grading the cognitive state of patients for clinician. J Psychiatr Res 1975; 12: 189198.
  • 24
    American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4 edn. Washington, DC: American Psychiatric Association, 1994.
  • 25
    McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939944.
  • 26
    Musha T, Okamoto Y. Forward and inverse problems of EEG dipole localization. Crit Rev Biomed Eng 1999; 27: 189239.
  • 27
    Hara J, Musha T, Shankle WR. Approximating dipoles from human EEG activity: the effect of dipole source configuration on dipolarity using single dipole models. IEEE Trans Biomed Eng 1999; 46: 125129.
  • 28
    Matsuda H, Mizumura S, Soma T, Takemura N. Conversion of brain SPECT images between different collimators and reconstruction processes for analysis using statistical parametric mapping. Nucl Med Commun 2004; 25: 6774.
  • 29
    Mizumura S, Kumita S. Stereotactic statistical imaging analysis of the brain using the easy Z-score imaging system for sharing a normal database. Radiat Med 2006; 24: 545552.
  • 30
    Matsuda H, Mizumura S, Nagao T et al. Automated discrimination between very early Alzheimer's disease and controls using an easy Z-score imaging system for multicenter brain perfusion SPECT. AJNR Am J Neuroradiol 2007; 28: 731736.
  • 31
    Habert MO, de Souza LC, Lamari F et al. Brain perfusion SPECT correlates with CSF biomarkers in Alzheimer's disease. Eur J Nucl Med Mol Imaging 2010; 37: 589593.
  • 32
    Tsolaki M, Sakka V, Gerasimou G et al. Correlation of rCBF (SPECT), CSF tau, and cognitive function in patients with dementia of the Alzheimer's type, other types of dementia, and control subjects. Am J Alzheimers Dis Other Demen 2001; 16: 2131.
  • 33
    Engler H, Forsberg A, Almkvist O et al. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain 2006; 129: 28562866.
  • 34
    Passero S, Rocchi R, Vatti G, Burgalassi L, Battistini N. Quantitative EEG mapping, regional cerebral blood flow, and neuropsychological function in Alzheimer's disease. Dementia 1995; 6: 148156.
  • 35
    Rodriguez G, Nobili F, Copello F et al. 99mTc-HMPAO regional Cerebral Blood Flow and quantitative Electroencephalography in Alzheimer's disease: a correlative study. J Nucl Med 1999; 40: 522529.
  • 36
    Riekkinen P, Buzsaki G, Riekkinen P Jr, Soininen H, Partanen J. The cholinergic system and EEG slow waves. Electroencephalogr Clin Neurophysiol 1991; 78: 8996.
  • 37
    Adler G, Brassen S. Short-term rivastigmine treatment reduces EEG slow-wave power in Alzheimer patients. Neuropsychobiology 2001; 43: 273276.
  • 38
    Shigeta M, Persson A, Viitanen M, Winblad B, Nordberg A. EEG regional changes during long-term treatment with tetrahydroaminoacridine (THA) in Alzheimer's disease. Acta Neurol Scand Suppl 1993; 149: 5861.